Market Overview

Benzinga's Top Downgrades

Related TEVA
UPDATE: Sterne Agee Upgrades Teva Pharmaceutical
Teva Pharmaceutical Releases 2015 Guidance, Sees Increased Generic Competition
Sofinnova Ventures Closes $500M Fund (Fox Business)
Related RVBD
Benzinga's M&A Chatter for Monday December 15, 2014
Network Stocks In Play Amid Riverbed Technology M&A

Analysts at Canaccord downgraded Teva Pharmaceutical Industries (NYSE: TEVA) from “buy” to “hold.” The target price for Teva has been raised from $50 to $45. Teva's shares closed at $37.96 yesterday.

Analysts at FBR Capital downgraded Riverbed Technology (NASDAQ: RVBD) from “outperform” to “market perform.” The target price for Riverbed has been lowered from $28 to $20. Riverbed's shares closed at $20.10 yesterday.

Analysts at Roth Capital downgraded Skullcandy (NASDAQ: SKUL) from “buy” to “neutral.” The target price for Skullcandy is set to $7. Skullcandy's shares closed at $6.61 yesterday.

CRT Capital downgraded Alpha Natural Resources (NYSE: ANR) from “buy” to “fair value.” The target price for Alpha Natural is set to $8. Alpha Natural's shares closed at $8.51 yesterday.

Latest Ratings for TEVA

DateFirmActionFromTo
Dec 2014Sterne AgeeUpgradesNeutralBuy
Dec 2014Deutsche BankMaintainsBuy
Dec 2014Bank of AmericaMaintainsBuy

View More Analyst Ratings for TEVA
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings

 

Related Articles (RVBD + ANR)

Around the Web, We're Loving...

Get Benzinga's Newsletters